SCHEMBL910567

SCHEMBL910567

O=[C]Cc1ccc(O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 0.57
ESR2 Q92731 2/20 0.57
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
HTR1A P08908 1/20 0.48
ADRA2A P08913 1/20 0.48
SLC6A2 P23975 1/20 0.48
CYP2C19 P33261 1/20 0.48
HTR3A P46098 1/20 0.48
BACE1 P56817 1/20 0.48
TAAR1 Q96RJ0 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CA2 P00918 4/20 0.46
BLM P54132 2/20 0.46
KMT2A Q03164 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
CAMK2A Q9UQM7 1/20 0.46
ABAT P80404 1/20 0.46
IDO1 P14902 1/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11139354 0.86 CYP3A4 (0.42) ESR1ESR2ALDH1A1KMT2ATDP1
SCHEMBL243411 0.79 TSHR (0.43) CA2CA12CA1CYP3A4TYR
SCHEMBL16904622 0.78 ESR1 (0.55) ESR1ESR2KDM4EALDH1A1HTR1A
SCHEMBL18427888 0.78 HRH3 (0.41) TAAR1CA2CA12CA1LMNA
SCHEMBL7103399 0.77 ESR1 (0.70) ESR1ESR2KDM4EALDH1A1HTR1A
SCHEMBL8023647 0.75 PGK1 (0.36) ESR1ESR2ALDH1A1CYP2C19BLM
SCHEMBL582045 0.75 ESR1 (0.59) ESR1ESR2KDM4EALDH1A1HTR1A
SCHEMBL96029 0.74 TAAR1 (0.48) TAAR1IDO1LMNA
SCHEMBL465580 0.74 TAAR1 (0.48) SLC6A2CYP2C19TAAR1KMT2AIDO1
SCHEMBL8625033 0.74 HRH3 (0.50) TAAR1CA2ABATCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 471 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11738087-B2 Lymph directing prodrugs MONASH UNIVERSITY (AU) 2023-08-29 US claimed
CN-101967094-B Phenylacetyl quinic acid of witlooves and ester compound thereof LI GUOYU 2013-06-19 CN claimed
US-20120277164-A1 GADD45BETA TARGETING AGENTS IMPERIAL INNOVATIONS LIMITED (GB) 2012-11-01 US claimed
EP-2491051-A2 GADD45BETA TARGETING AGENTS Imperial Innovations Limited (GB) 2012-08-29 EP claimed
WO-2011048390-A2 GADD45BETA TARGETING AGENTS IMPERIAL INNOVATIONS LIMITED (GB) 2011-04-28 WO claimed
CN-101967094-A Phenylacetyl quinic acid of witlooves and ester compound thereof GUOYU LI 2011-02-09 CN claimed
EP-2210900-A2 Analogues of GLP-1 IPSEN PHARMA (FR) 2010-07-28 EP claimed
US-20090300800-A1 D-Amino Acid a Selectable Marker for Barley (Hordeum Vulgare L.) Transformation BASF PLANT SCIENCE GMBH (DE) 2009-12-03 US claimed
EP-1711523-A4 ANALOGUES OF GLP-1 SOD CONSEILS RECH APPLIC (FR) 2008-05-21 EP claimed
US-20070248996-A1 Modulators of beta-amyloid peptide aggregation comprising D-amino acids PARAECIS PHARMACEUTICALS, INC. (US) 2007-10-25 US claimed
US-4533495-A Method of producing 2-azetidinone-1-sulfonic acid compounds TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1985-08-06 US claimed
EP-0082568-B1 RETRO-INVERSO ANALOGUES OF C-TERMINAL PENTA AND HEXAPEPTIDES OF SUBSTANCE P. ANIC S.p.A. (IT) 1984-11-21 EP claimed
US-4439360-A Retro-inverso analogues of C-terminal penta and hexapeptides of Substance P ANIC S.P.A. (IT) 1984-03-27 US claimed
US-4401660-A TYLOSINS; VETERINARY MEDICINE; PASTEURELLA; ANIMAL GROWTH REGULATORS ELI LILLY AND COMPANY (US) 1983-08-30 US claimed
EP-0082568-A2 Retro-inverso analogues of C-terminal penta and hexapeptides of substance P. ANIC S.p.A. (IT) 1983-06-29 EP claimed
EP-0000931-B1 ENZYMATIC CLEAVAGE OF N-ACYL-THIENAMYCINS MERCK & CO. INC. (US) 1982-04-14 EP claimed
US-4162193-A Enzymatic cleavage of N-acyl-thienamycins MERCK & CO., INC. (US) 1979-07-24 US claimed
US-4159267-A Novel silyl ester azetidine-2-sulfenate intermediates and process for preparing desacetoxycephalosporins ELI LILLY AND COMPANY (US) 1979-06-26 US claimed
EP-0000931-A1 Enzymatic cleavage of N-acyl-thienamycins MERCK & CO. INC. (US) 1979-03-07 EP claimed
US-3972774-A BY AN ESTERASE ENZYME FROM BACILLUS ELI LILLY AND COMPANY (US) 1976-08-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070248996-A1 Modulators of beta-amyloid peptide aggregation comprising D-amino acids APP, IAPP, BACE1 ESR1 3309/4885ESR2 1939/4885KDM4E 3643/4885
US-11738087-B2 Lymph directing prodrugs MLNR, ABCB11, MLN ESR1 1417/4885ESR2 2975/4885KDM4E 1955/4885
US-20120277164-A1 GADD45BETA TARGETING AGENTS DDB1, CCL2, DDIT3 ESR1 3378/4885ESR2 2174/4885KDM4E 4430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.